PF-Atlas › Clinical Trials › NCT02267655
3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
inhaled Nitric Oxide - 30 mcg/kg IBW/hr · Phase 1
Registry ID
NCT02267655
Phase
Phase 1
Status
Completed
Drug / intervention
inhaled Nitric Oxide - 30 mcg/kg IBW/hr
Sponsor
Bellerophon
Start
2015-05
Enrollment
8
Locations
1
About this trial
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of short term a) iNO administration and b) nitric oxide (NO) cylinder concentration using the investigational medical device INOpulse® DS-C in subjects with WHO Group 3 PH associated with COPD on LTOT (Part 1) and in Subjects with WHO Group 3 PH associated with Idiopathic Pulmonary Fibrosis (IPF) on LTOT (Part 2 and Part 3)
Explore related
Medical disclaimer. This page summarizes public trial data for NCT02267655 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.